Zika virus spreads to people primarily through the bite of an infected Aedes species mosquito, but it can also be sexually transmitted. Zika virus was first discovered in 1947 and is named after the Zika Forest in Uganda. In 1952, the first human cases of Zika were detected. Zika virus has become a highly researched disease due to increase in incidences from 2007 to 2016, when the virus spread eastward, across the Pacific Ocean to the Americas. In 2015-2016 Zika virus epidemic reached pandemic levels. The Zika envelope (E) protein composes the majority of the virion surface and it is involved with replication, such as host cell binding and membrane fusion.
The symptoms of Zika infection vary from non-existant to visible rash, fever, headaches and conjunctivitis. It is usually non life threatening, but has been associated to microcephaly in unborn fetuses when passed by an infected pregnant mother.
The sequence of the envelope protein is derived from the African strain (all strains share very high identity in this region).
Description:Recombinant protein corresponding to aa291-690 from Zika virus envelope (E protein), expressed in Insect cells.
Molecular Weight:~50kD
Applications:Suitable for use in ELISA and Lateral Flow. Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
Size：100ug
Source Antigen：Recombinant, Insect cells
Grade：Purified
Purity：Purified (~85%)
Form：Supplied as liquid in PBS, pH 7.4, 0.05% sodium azide.
